RESULTS:
A total of 376 patients were included e 121 patients who received late preterm steroids and 255 patients who served as a historical control. Preliminary data demonstrates no statistically significant differences in maternal demographics. A statistically significant difference in birthweight was initially noted between the groups (p < 0.001) however when controlled for there was no difference (p ¼ 0.206).
Initially, there was no statistically significant difference between the groups of neonates requiring respiratory treatment in the first 72 hours (p ¼ 0.069), however, results became statistically significant when birthweight was controlled (p ¼ 0.045). Neonates within the betamethasone group had higher rates of hypoglycemia compared to the control group (p ¼ 0.012). The significance was retained even after controlling for the birthweight (p ¼ 0.007). OBJECTIVE: Premature cervical remodeling is likely an obligatory step in the pathogenesis of spontaneous preterm birth. Previously, we have shown Replens, the vehicle used to deliver vaginal progesterone, will prevent preterm birth in an inflammatory mouse model. However, it remains unknown if Replens will have an impact on cervical remodeling. Therefore, we hypothesize Replens will prevent preterm birth and cervical remodeling by inhibiting the inflammation induced functional changes to the cervical epithelial barrier. STUDY DESIGN: The integrity of the epithelial cell barrier was assessed using an in vitro permeability assay. Immortalized ectocervical cells were grown in a monolayer across a semi permeable membrane at a concentration of 2 x 10 5 cells well. Cells were treated with 10% and 25% solutions of Replens in saline for 2 hours prior to treatment with 25ug/ml of lipopolysaccharide (LPS). After 24 hours, FITCdextran was added for 2 hours. The extent of permeability was determined by measuring the fluorescence on the receiver plates well solution. RESULTS: Exposure to LPS alone significantly increased the permeability of ectocervical cells (p<0.05), and pretreatment with Replens prevented the LPS induced increase in permeability at concentrations of 10% (p<0.001) and 25% (p<0.001) compared to treatment with LPS only. CONCLUSION: These studies demonstrate Replens prevents the LPS induced breakdown of the ectocervical epithelial barrier. Further research is needed to determine if Replens can be utilized as a therapeutic agent to prevent preterm birth.
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